Notably, among these proteins, CSF1 is a key regulator of monocyte recruitment and activation that has not been previously well studied in the context of NAFLD, but may serve as an innovative therapeutic target in this regard. This evidence concerns the gene CSF1 and metabolic dysfunction-associated steatotic liver disease.